Seasonal Depression Treatment 2026: Light, Bupropion XL, CBT, and When They Fail

What it is

Seasonal depression is major depression on a calendar

Seasonal affective disorder is not a separate illness. It is major depressive disorder whose episodes recur in the same season each year and lift when the season turns. Most cases are winter-pattern, with symptoms that last about four to five months. NIMH estimates millions of Americans have it; the Cochrane reviews put prevalence between 1.5 and 9 percent depending on how far north a population lives.

The winter form tends to look a particular way: oversleeping, carbohydrate craving, weight gain, heavy fatigue, and social withdrawal, on top of the low mood that defines any depressive episode. The rating scale used in the trials below, the SIGH-SAD, adds those seven items to the standard Hamilton scale for exactly that reason. Women are diagnosed more often than men, and the pattern is more common in people who also have depression at other times or bipolar disorder, especially bipolar II.

Two facts drive everything that follows. First, the episode is predictable, which is what makes prevention possible at all. Second, it is still a major depressive episode, which is why the treatments that work for depression generally, including the advanced ones, apply to it.

First-line treatment

What the trials say about light, bupropion XL, and CBT-SAD

The table gives the number behind each first-line option, from the trial or meta-analysis that produced it. These are group results. A clinician matches the option to the person: a bipolar history, a sleep schedule, an existing antidepressant, and how early in the season you are all change the choice.

Treatment	What the evidence shows	How it is used
Bright light therapy	Eight randomized trials pooled in 2005: effect size 0.84 against placebo light, in the range of antidepressant trials. In the Can-SAD trial, 10,000 lux for 30 minutes each morning matched fluoxetine 20 mg: 67 percent responded in each group, and light worked faster in week one.	10,000 lux, 30 to 45 minutes, first thing in the morning, every day from fall to spring (NIMH).
Bupropion XL	The only medicine the FDA has approved to prevent seasonal depressive episodes. In three placebo-controlled trials, 84.3 percent of people on bupropion XL stayed depression-free through the season against 72.0 percent on placebo. Cochrane rates that moderate-quality evidence: risk of a new episode cut by 44 percent.	Per the label: start in the autumn before symptoms, 150 mg then 300 mg once daily in the morning, continue through winter, taper in early spring.
CBT adapted for SAD	Head to head with light therapy, the two treatments were equal in the first winter. Two winters later, CBT-SAD had fewer recurrences, 27.3 percent against 45.6 percent, and more remissions, 68.3 percent against 44.5 percent.	NIMH describes the studied format as two weekly group sessions for six weeks.
Other antidepressants	SSRIs such as fluoxetine and sertraline treat the depressive episode once it has started; NIMH lists them as sometimes used. Cochrane found no prevention trials of any antidepressant other than bupropion XL.	Allow four to eight weeks for a full effect, the same as for any depressive episode.

Effect sizes and response rates are from Golden et al. 2005 (meta-analysis of eight bright-light trials), Lam et al. 2006 (Can-SAD, 96 patients, four Canadian centers), Rohan et al. 2016 (177 adults followed two winters), and sections 14.2 and 6.1 of the Wellbutrin XL prescribing information. In the bupropion trials, 9 percent of people on the drug and 5 percent on placebo stopped because of side effects; insomnia and headache led the list.

Timing

Start before the clock change, not after the first bad week

Daylight saving time ends at 2 a.m. on Sunday, November 1, 2026. Sunset jumps an hour earlier that evening, and for many people with winter-pattern SAD the weeks that follow are when the episode settles in. Every prevention trial that has worked started treatment before that point.

Bupropion XL. The label is specific: initiate in the autumn, prior to the onset of depressive symptoms; the trials started between September and November. Start at 150 mg once daily in the morning, with the option to move to 300 mg after seven days; continue through the winter; taper and stop in early spring, dropping to 150 mg before stopping. Doses above 300 mg were not studied for SAD.
Light therapy. NIMH says people with a history of winter-pattern SAD may benefit from starting before the fall. In practice that means the box is on the breakfast table in October, used every morning, not pulled out of a closet in January.
CBT-SAD. The six-week course in the Rohan trial was delivered during the winter episode, and its advantage showed up in the second winter. A course this fall is a plan for next fall as much as this one.
An appointment.If last winter's treatment did not work, book the reassessment in October. Waiting for the episode to prove itself costs the weeks that prevention needs.

The prevention evidence, honestly

Four Cochrane reviews looked at preventing SAD. Only one found moderate-quality evidence.

In 2019, one Cochrane group published four reviews on preventing seasonal affective disorder in adults with a history of it: antidepressants, light therapy, psychological therapies, and melatonin or agomelatine. Each searched the same 3,745 citations. The table shows what survived.

Preventive strategy	What the trials found	What it costs
Bupropion XL, started before symptoms	Three randomized trials, 1,100 people. Risk of a seasonal episode 0.56 of placebo. Moderate-quality evidence.	More headaches (moderate-quality evidence), insomnia and nausea (low-quality). Cochrane's own line: even in a high-risk group, three out of four people will not benefit and will carry the side-effect risk.
Light therapy, started before symptoms	One trial of 46 people from the 1990s, using 2,500-lux visors. Fewer people became depressed with light than with nothing (43 percent against 67 percent), but the interval is too wide to call it. Very low-quality evidence.	No adverse-event data were reported. The acute-treatment evidence above is far stronger than the prevention evidence.
Psychological therapy, started in spring	One trial of 46 people: mindfulness-based cognitive therapy against usual care. 65 percent against 74 percent developed depression the next winter, a difference the trial could not distinguish from chance. Very low-quality evidence.	CBT-SAD's two-winter data come from acute treatment during the winter, not from a spring prevention course.

Cochrane's numbers needed to treat put the bupropion result in human terms. Where 30 percent of people relapse each winter, eight people take bupropion XL all season for one of them to be spared an episode. Where 60 percent relapse, four do. The review's conclusion is that the decision should rest on the patient's preference once the trade-off is explained, and that other options with fewer side effects deserve a hearing.

When it does not lift

What a clinician checks before adding anything new

A winter that does not respond to a light box and an antidepressant is not unusual, and it is not a dead end. Before a next treatment is chosen, a reassessment answers four questions. Most of the time one of them changes the plan.

1
Confirm the pattern is seasonal, and only seasonal
The diagnosis is major depression with a seasonal pattern: episodes that start and end at about the same time each year, with full remission in between. NIMH notes the pattern is more common in people who also have bipolar disorder, especially bipolar II. A clinician screens for hypomania before starting light or bupropion, because both can trigger it.
2
Check the first-line course was adequate
Light therapy fails often for a practical reason: a box under 10,000 lux, a session shorter than 30 minutes, light used in the evening instead of the morning, or a start in December when the episode is already established. Bupropion XL fails when it is started after symptoms begin; the label's trials started it in September to November.
3
Count the trials honestly
The SPRAVATO prescribing information describes the people in its treatment-resistant depression trials this way: in the current episode, they had not responded adequately to at least two different antidepressants of adequate dose and duration. A winter episode that meets that description is treatment-resistant regardless of the season it arrived in, and that opens a different conversation, covered in the next section.
4
Look for what else is driving the winter
Sleep, alcohol, thyroid function, medical illness, and life events that recur each winter can all produce a pattern that looks seasonal. A reassessment names them before another treatment is added.

This site's guide to what happens when antidepressants fail covers the optimize, switch, combine, and augment decisions in detail, and the treatment-resistant depression hub explains what a specialist reassessment includes.

Advanced care and the seasonal pattern

TMS, esketamine, and ECT are discussed for the episode, not the season

None of the advanced treatments has been studied as a way to prevent a winter episode, and none is used that way. What they treat is a major depressive episode that has not responded to adequate medication trials. The season it arrived in does not change the eligibility, and the one published look at the question suggests it does not change the result either.

TMS. First approved by the FDA for major depressive disorder in 2008, according to the American Psychiatric Association. In a 2023 Toronto series of 127 people treated with high-frequency rTMS, 46 percent had a seasonal pattern on a standard screening inventory. Their improvement on the Hamilton scale and their remission rate (34 percent against 30 percent) were no different from the rest, and the atypical symptoms that mark winter depression, oversleeping and overeating, improved just as much. The authors concluded rTMS may be a viable treatment for this group. A course is daily outpatient sessions over several weeks; the cost and insurance guide explains what Medicare and commercial plans require first.
SPRAVATO (esketamine). FDA-approved for treatment-resistant depression in adults, given as a nasal spray under supervision in a certified clinic. In the trials behind that indication, described in section 14.1 of the prescribing information (revised 09/2026), patients had not responded adequately to at least two different antidepressants of adequate dose and duration in the current episode. The criterion counts treatments, not seasons.
ECT. Hospital-based treatment under anesthesia, considered when an episode is severe, when safety cannot wait, or when other treatments have failed. The life after ECT guide covers the relapse window that makes continuation treatment part of any ECT plan.
What to bring to the appointment.The seasons your episodes began and ended for the past three years, every treatment tried with its dose and how long you stayed on it, and the light box's brightness rating and your actual daily minutes. That history is what separates an inadequate first-line course from a resistant one.

Common questions

Questions people ask about treating seasonal depression

When should I start treating seasonal depression in 2026?

Before the symptoms, not after. The bupropion XL label says to start in the autumn before seasonal symptoms begin; its trials started between September and November. NIMH says people with a history of winter-pattern SAD may benefit from starting light therapy, psychotherapy, or medication before the fall. Clocks fall back on November 1, 2026, which many people notice as the week their mood drops. If your pattern starts then, October is the month to act.

What helps with seasonal depression?

Four approaches with evidence: bright light therapy (10,000 lux, 30 to 45 minutes each morning), cognitive behavioral therapy adapted for SAD, antidepressant medication, and, for prevention, bupropion XL started before the season. Vitamin D has mixed results. For a depressive episode that has not responded adequately to at least two different antidepressants of adequate dose and duration, the threshold used in the SPRAVATO treatment-resistant depression trials, the options widen to TMS, esketamine, and ECT, the same as for any treatment-resistant depression.

What are the worst months for seasonal depression?

For winter-pattern SAD, symptoms typically last about four to five months of the year, from late fall into early spring. Risk is higher farther north, where winter days are shorter. The clock change on the first Sunday of November moves an hour of daylight from evening to morning, and for many people the weeks after it are when the episode takes hold. A summer-pattern form also exists, but it is less common.

Is TMS an option for seasonal depression?

The FDA first approved TMS for major depressive disorder in 2008, according to the American Psychiatric Association, and a seasonal pattern does not change that indication. A 2023 analysis of 127 people treated with rTMS found that the 58 with a seasonal pattern improved as much as those without one (remission 34 percent against 30 percent). There is no trial of TMS as a seasonal prevention strategy, so it is discussed for an episode that has not responded, not as a winter routine.

Does light therapy work for depression that is not seasonal?

The 2005 meta-analysis found bright light alone helped nonseasonal depression (effect size 0.53 in three studies), but bright light added to an antidepressant did not (effect size near zero in five studies). Light therapy is a first-line treatment for winter-pattern SAD specifically.

What vitamins are helpful for seasonal depression?

NIMH lists vitamin D as one of four treatment categories for winter-pattern SAD but says studies testing it have produced mixed results. No vitamin has shown the effect sizes that light therapy, CBT-SAD, or bupropion XL have. Ask a clinician to check a level before supplementing rather than treating a season with a supplement alone.

Sources

Where each figure comes from

Source links support education, not a personal treatment recommendation. Dosing figures are quoted from the prescribing information for context and are not a prescription. Diagnosis and treatment decisions belong to a qualified clinician.